Prolia (Denosumab) Cost in Minnesota: 2026 Pricing, Insurance, and Savings Guide

Denosumab is a RANK ligand (RANKL) inhibitor sold under two brand names with different doses and indications: Prolia (60 mg subcutaneous, every six months, for osteoporosis and related bone loss) and Xgeva (120 mg, monthly, for cancer-related bone events). This page covers Prolia. A compounded version prepared by a 503A pharmacy is a distinct, non-FDA-approved preparation, not a generic.

What actually determines what a Minnesota patient pays is not the drug's list price but which payer, if any, is billing it. Cash-pay patients face the full manufacturer price for a physician-administered biologic; Medicare Part B patients face a 20% coinsurance after the Part B deductible; commercially insured patients face a specialty-tier copay that the Amgen Savings Card can largely offset; and Medicaid enrollees face a $0-to-low copay once prior authorization is approved. Exact dollar figures below are volatile, insurer-specific, and not verifiable from FDA or clinical-trial sources, so they should be confirmed directly with the pharmacy, clinic billing office, or health plan before a patient relies on them.

What Prolia costs in Minnesota without insurance

Prolia is billed as a physician-administered specialty injectable rather than a retail pharmacy pickup, and it carries Medicare's J-code J0897. Amgen sets a national wholesale acquisition cost for the product, and that price is publicly listed in the FDA's drug approval record, but actual patient-facing cash prices at Minnesota clinics and specialty pharmacies are not published anywhere we can verify from primary sources. Reported cash prices for Prolia elsewhere in the country have generally clustered in the $1,000-$1,800 per-dose range, but this figure requires direct confirmation with a specific Minnesota pharmacy or infusion center before a patient budgets around it, prices change, and no Minnesota-specific price list is available as a source for this article (verification needed, as of 2026-05-27).

Because dosing is every six months, the annual out-of-pocket burden for a fully uninsured patient is roughly double whatever the confirmed per-dose price turns out to be.

Cash-pay reduction strategies

Ask the prescribing clinic whether it bills under a buy-and-bill arrangement versus a specialty pharmacy fill; the two billing paths can produce different patient-facing prices. Discount coupon aggregators sometimes list denosumab discounts, but the size of any discount is plan- and platform-specific and should be verified at the time of purchase rather than assumed from a national average.

Minnesota Medicaid coverage

Minnesota Medical Assistance (Medicaid) can cover Prolia with prior authorization. Typical PA documentation for denosumab across Medicaid programs includes a DXA T-score in the osteoporotic range or a history of fragility fracture, along with evidence that the patient has tried, failed, or cannot tolerate an oral bisphosphonate such as alendronate, criteria consistent with the enrollment population studied in the pivotal FREEDOM trial (PMID 19671655). Exact Minnesota Department of Human Services PA criteria, approval periods, and turnaround times change over time and should be confirmed against the current Minnesota Health Care Programs formulary rather than assumed from this page.

MinnesotaCare and Medicaid managed-care organizations operating in the state (for example UCare, Hennepin Health, and Blue Plus) each maintain their own PA forms. Whether their clinical criteria and turnaround times match each other or the fee-for-service program is a plan-specific fact that needs direct confirmation, not a generalization from one plan to all.

Commercial insurance in Minnesota

Most major commercial carriers selling in Minnesota, including Blue Cross Blue Shield of Minnesota, UnitedHealthcare, and Medica, place Prolia on a specialty formulary tier and commonly require step therapy with a generic bisphosphonate first, with exceptions typically available for documented intolerance or contraindication (for example esophageal disorders or significant renal impairment). Specific coinsurance percentages, deductible interactions, and step-therapy exception language differ by plan and plan year, and should be confirmed against the member's current summary of benefits rather than treated as fixed facts.

Medicare Part B

Prolia is billed under Medicare Part B, not Part D, because it is physician-administered. Under Original Medicare, Part B generally pays 80% of the allowable amount after the annual Part B deductible is met, leaving the patient responsible for the remaining 20% coinsurance unless a Medigap supplemental plan covers it. The Part B deductible amount changes annually and should be confirmed for the current benefit year from CMS rather than carried forward from a prior year. Medicare Advantage plans sold in Minnesota are required to cover Part B drugs at least as favorably as Original Medicare, but specific cost-sharing structures vary by plan.

The Amgen Prolia Savings Card

Amgen offers a savings card for patients with commercial (private) insurance. Patients enrolled in Medicare, Medicaid, Tricare, or other federal or state healthcare programs are excluded by federal anti-kickback rules that govern manufacturer copay assistance for government-insured patients, this is a standard feature of manufacturer savings cards generally, not a Minnesota-specific rule. The card is applied after the primary insurer adjudicates the claim, covering some or all of the patient's remaining cost share up to the program's annual per-dose and per-year caps. Program terms, caps, and eligibility rules are set by Amgen and can change; patients should confirm current terms at the time of use rather than assume the terms described in older marketing material still apply (verification needed, as of 2026-05-27).

Compounded denosumab in Minnesota

Licensed 503A pharmacies can compound denosumab pursuant to a patient-specific prescription under Section 503A of the Federal Food, Drug, and Cosmetic Act. Minnesota's Board of Pharmacy licenses and inspects compounding pharmacies operating in the state, and patients considering a compounded product should confirm the pharmacy's current Minnesota license and its adherence to USP sterile compounding standards.

This is a meaningful evidence gap, not a minor caveat: the fracture-reduction data described below come entirely from trials of the FDA-approved, manufactured product. No large randomized trial has evaluated a compounded denosumab formulation for fracture prevention, immunogenicity, or pharmacokinetic equivalence to Prolia. A patient who chooses a compounded version for cost reasons is accepting a formulation whose clinical performance has not been independently verified, regardless of price.

Telehealth prescribing

Minnesota permits a licensed prescriber to evaluate a patient by synchronous audio-video visit and issue a Prolia prescription without a prior in-person visit, provided an appropriate provider-patient relationship is established. The subcutaneous injection itself still requires an in-person visit to a clinic or infusion site, since denosumab is not self-administered. Telehealth is most useful for the initial evaluation, treatment planning, DXA result review, and follow-up monitoring rather than the injection itself. Whether a specific insurer reimburses the telehealth visit at parity with an in-person visit is a plan-level fact that should be confirmed with that plan.

Patient assistance and discount pathways

Amgen operates a patient assistance program for uninsured or underinsured patients meeting income criteria; current income thresholds and application requirements should be confirmed directly with Amgen rather than assumed from prior-year figures. Minnesota hospital systems, including academic and safety-net systems in the state, maintain financial assistance policies required under state and federal law, and patients receiving Prolia in a hospital outpatient setting may qualify depending on income. Some Minnesota clinics, particularly federally qualified health centers, participate in the 340B Drug Pricing Program, which allows covered entities to acquire outpatient drugs including Prolia at a discounted acquisition cost; whether that discount is passed through to an individual patient's bill depends on the entity's own billing policy and is not guaranteed by the 340B program itself.

Why Prolia is prescribed, and what the trial evidence actually shows

Denosumab is a fully human monoclonal antibody that binds RANKL, a signaling protein required for osteoclast formation and activity. By inhibiting RANKL, denosumab reduces bone resorption and increases bone mineral density. The FDA approved Prolia in 2010 for postmenopausal women with osteoporosis at high fracture risk, with later approvals covering additional populations including men with osteoporosis and patients on aromatase-inhibitor or androgen-deprivation therapy.

In the FREEDOM trial (N=7,868 postmenopausal women with osteoporosis), denosumab 60 mg every six months reduced new radiographic vertebral fractures to 2.3% versus 7.2% with placebo over 36 months (PMID 19671655). The FREEDOM open-label extension followed a subset of patients for up to ten years and reported continued fracture-risk reduction with ongoing treatment (PMID 28546097). These results apply to the population studied, largely postmenopausal women with osteoporosis, and should not be assumed to transfer without qualification to other indications such as glucocorticoid-induced bone loss.

The discontinuation risk that changes the cost conversation

Stopping denosumab without a follow-on antiresorptive is associated with rapid bone turnover rebound and reports of multiple vertebral fractures within roughly 7 to 16 months of the last dose in a post hoc analysis of the FREEDOM trial and its extension (PMID 29105841). Because of this, cost-driven decisions to skip or delay a dose, switch to a compounded product mid-course, or stop therapy when insurance coverage lapses carry a clinical risk that is distinct from ordinary medication non-adherence. Guideline bodies including the Endocrine Society and the American Association of Clinical Endocrinology recommend transitioning to a bisphosphonate, typically zoledronic acid, when denosumab is discontinued, rather than stopping without a follow-on plan. Any patient considering stopping Prolia for cost reasons should raise the discontinuation-rebound risk with the prescriber before missing a scheduled dose, and should not attempt to self-manage the timing of a switch.

What is established, what is plausible, and what is not established

Established: Prolia's FDA-approved indications and dosing schedule; the RANKL mechanism; the FREEDOM trial's fracture-reduction results in postmenopausal women with osteoporosis; the discontinuation rebound-fracture signal; Medicare's Part B billing pathway for physician-administered drugs; the existence of manufacturer savings-card and patient-assistance programs generally.

Plausible but unverified for this page: Specific Minnesota cash-pay price ranges, specific Minnesota Medicaid PA turnaround times, and specific commercial-plan coinsurance percentages. These likely exist and vary by pharmacy, plan, and year, but no Minnesota-specific primary source was available to confirm exact figures at the time of writing.

Not established: Clinical equivalence of compounded denosumab to the FDA-approved product; any claim that Minnesota cash prices differ systematically from national prices; savings-card terms beyond what Amgen currently publishes.

Verification checklist: stable facts vs. facts you must confirm before paying

Frequently asked questions

References

1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis (FREEDOM trial). N Engl J Med. 2009;361(8):756-765. https://pubmed.ncbi.nlm.nih.gov/19671655/
2. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523. https://pubmed.ncbi.nlm.nih.gov/28546097/
3. Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190-198. https://pubmed.ncbi.nlm.nih.gov/29105841/
4. U.S. Food and Drug Administration. Prolia (denosumab) approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320
5. Health Resources and Services Administration. 340B Drug Pricing Program. https://www.hrsa.gov/opa